Tolerability, Safety, and Benefits of Risperidone in Children and Adolescents with Autism: 21-Month Follow-up After 8-Week Placebo-Controlled Trial

Objective: Risperidone has demonstrated efficacy for acute (8 week) and intermediate length (6 month) management of severe irritability and aggression in children and adolescents with autism. Less is known about the long-term effects of risperidone exposure in this population. We examined the tolera...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Child Adolesc Psychopharmacol
Päätekijät: Aman, Michael, Rettiganti, Mallikarjuna, Nagaraja, Haikady N., Hollway, Jill A., McCracken, James, McDougle, Christopher J., Tierney, Elaine, Scahill, Lawrence, Arnold, L. Eugene, Hellings, Jessica, Posey, David J., Swiezy, Naomi B., Ghuman, Jaswinder, Grados, Marco, Shah, Bhavik, Vitiello, Benedetto
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Mary Ann Liebert, Inc. 2015
Aiheet:
Original Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4545698/
https://ncbi.nlm.nih.gov/pubmed/26262903
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/cap.2015.0005
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia